Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database von Jin, Zhaohui, Dixon, Jesse G, Fiskum, Jack M, Parekh, Hiral D, Sinicrope, Frank A, Yothers, Greg, Allegra, Carmen J, Wolmark, Norman, Haller, Daniel, Schmoll, Hans-Joachim, de Gramont, Aimery, Kerr, Rachel, Taieb, Julien, Van Cutsem, Eric, Tweleves, Christopher, O'Connell, Michael, Saltz, Leonard B, Sadahiro, Sotaro, Blanke, Charles D, Tomita, Naohiro, Seitz, Jean-Francois, Erlichman, Charles, Yoshino, Takayuki, Yamanaka, Takeharu, Marsoni, Silvia, Andre, Thierry, Mahipal, Amit, Goldberg, Richard M, George, Thomas J, Shi, Qian

Volltext

Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database von Franko, Jan, Yin, Jun, Adams, Richard A, Zalcberg, John, Fiskum, Jack, Van Cutsem, Eric, Goldberg, Richard M, Hurwitz, Herbert, Bokemeyer, Carsten, Kabbinavar, Fairooz, Curtis, Alexandra, Meyers, Jeffery, Chibaudel, Benoist, Yoshino, Takayuki, de Gramont, Aimery, Shi, Qian

Volltext

Trajectories of body weight change and survival among mCRC patients treated with systemic therapy: Pooled analysis from the ARCAD database von Franko, Jan, Yin, Jun, Adams, Richard, Zalcberg, John Raymond, Fiskum, Jack, VanCutsem, Eric, Goldberg, Richard M., Hurwitz, Herbert I., Bokemeyer, Carsten, Kabbinavar, Fairooz F., Curtis, Alexandra, Chibaudel, Benoist, Yoshino, Takayuki, De Gramont, Aimery, Shi, Qian

Volltext

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies von Hubbard, Joleen M., Yin, Jun, Schenk, Erin L., Qin, Rui, Reid, Joel M., Strand, Carrie, Fiskum, Jack, Menefee, Michael, Lin, Grace, Doyle, L. Austin, Ivy, Percy, Erlichman, Charles, Adjei, Alex, Haluska, Paul, Costello, Brian A.

Volltext